Terns Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 21.53 million compared to USD 13.77 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.55 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.095 USD | +2.78% | -1.14% | -6.47% |
13/05 | Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Terns Pharmaceuticals, Inc. Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.47% | 384M | |
+63.80% | 62.59B | |
-1.27% | 41.18B | |
+44.76% | 40.29B | |
-8.29% | 27.9B | |
+12.70% | 26.21B | |
-21.60% | 19.09B | |
+5.30% | 13.08B | |
+25.47% | 12.26B | |
+28.41% | 12.05B |
- Stock Market
- Equities
- TERN Stock
- News Terns Pharmaceuticals, Inc.
- Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023